Velmarto (China) (eratrectinib)
An investigational treatment for NTRK Fusion Cancer.
The same compound appears under different names depending on the context. Here is how to identify Eratrectinib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Eratrectinib
- Brand name
- Velmarto (China)
- Development code
- VC004
- International names
- Velmarto (China), VC004
- Drug class
- TRK inhibitor (next generation)
- Manufacturer
- Jiangsu Vcare PharmaTech
A next-generation oral TRK inhibitor from Jiangsu Vcare PharmaTech, approved in China in June 2026 as Velmarto for NTRK fusion solid tumors, with a 68.5% response rate in its pivotal trial. It has not been studied in the United States.
How Eratrectinib works
Eratrectinib blocks the TRK proteins produced by NTRK gene fusions and was designed so that the resistance mutations that stop Vitrakvi and Rozlytrek working do not stop it. Its pivotal trial enrolled both patients new to TRK inhibitors and patients who had progressed on one.
Mechanism: Next-generation selective TRK inhibitor designed to overcome resistance to first-generation TRK inhibitors
Side effects and safety
Vcare has not published side effect rates in its public results announcement. TRK inhibitors as a class cause on-target nervous system effects, including dizziness, weight gain, tingling or numbness and pain when the drug is stopped, and the Chinese label will carry eratrectinib's own rates. Patients on any TRK inhibitor are monitored for liver enzyme changes.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Clinical trial results
In the pivotal VC004-101 trial reported by Vcare in August 2026, the overall response rate was 68.5%, rising to 89.7% among patients followed for more than 6 months; 75.7% of patients were progression-free at 2 years, 85.5% of responses were still ongoing at 2 years, and median overall survival was 40.7 months[1]. The earlier Phase 1 study published in Experimental Hematology and Oncology in 2026 reported a 70% response rate (21 of 30) at the recommended dose[2]. A single-arm Phase 3 confirmatory trial (NCT06658353, 54 patients, age 12 and older) is recruiting in China[3].
Main registered trial: NCT06658353 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Development history
Jiangsu Vcare PharmaTech developed eratrectinib as VC004. China's regulator approved it in June 2026 under the brand name Velmarto, and approved its companion diagnostic test, PanTRKare, on August 6, 2026. No application has been announced outside China.
Explore NTRK Fusion Cancer trials
Other NTRK Fusion Cancer treatments
Where Eratrectinib is available
Approved outside the United States, not by the FDA
Eratrectinib (Velmarto (China), VC004) has been approved by a regulator outside the United States but has no FDA approval, so it cannot be prescribed in the US. US patients can receive it only through a clinical trial that enrolls at US sites, if one exists. Check the trial record below for current sites and status.
Common questions about Eratrectinib
▸What is Eratrectinib (Velmarto (China))?
A next-generation oral TRK inhibitor from Jiangsu Vcare PharmaTech, approved in China in June 2026 as Velmarto for NTRK fusion solid tumors, with a 68.5% response rate in its pivotal trial. It has not been studied in the United States.
▸How does Eratrectinib work?
Eratrectinib blocks the TRK proteins produced by NTRK gene fusions and was designed so that the resistance mutations that stop Vitrakvi and Rozlytrek working do not stop it. Its pivotal trial enrolled both patients new to TRK inhibitors and patients who had progressed on one.
▸What are the side effects of Eratrectinib?
Vcare has not published side effect rates in its public results announcement. TRK inhibitors as a class cause on-target nervous system effects, including dizziness, weight gain, tingling or numbness and pain when the drug is stopped, and the Chinese label will carry eratrectinib's own rates. Patients on any TRK inhibitor are monitored for liver enzyme changes.
▸Is Eratrectinib FDA approved?
Eratrectinib is currently in phase 3 clinical trials for NTRK Fusion Cancer. It has not yet received FDA approval.
▸Is eratrectinib approved in the United States?
No. It was approved in China in June 2026 as Velmarto. Vcare has not announced a US application, and its trials are at Chinese sites only.
▸How effective is eratrectinib?
In the pivotal trial reported by Vcare, 68.5% of patients responded overall and 89.7% of those followed for more than 6 months, with 75.7% progression-free at 2 years and a median survival of 40.7 months. These are single-arm results and have not been compared head to head with the US-approved drugs.
▸Does eratrectinib work after a first-generation TRK inhibitor?
It was designed to, and its pivotal trial included patients who had progressed on a first-generation drug. Vcare has not published a separate response rate for that subgroup.
▸Can US patients join an eratrectinib trial?
No. The Phase 3 confirmatory trial (NCT06658353) recruits in China only.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Jiangsu Vcare PharmaTech · 2026-08-12. Vcare PharmaTech news on eratrectinib (VC004) pivotal results. https://en.vcarepharmatech.com/news_detail/2087737290893774848-54-6.html
- Experimental Hematology and Oncology. Phase 1 study of eratrectinib (VC004) in NTRK fusion-positive solid tumors. https://link.springer.com/article/10.1186/s40164-026-00799-9
- ClinicalTrials.gov. A Phase 3 study of VC004 in patients with NTRK fusion solid tumors. https://clinicaltrials.gov/study/NCT06658353